Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,122.96 +15.88 (+1.43%)
Streaming Delayed Price Updated: 9:49 AM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
Topics Artificial Intelligence
News headline image
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight ↗
The U.S. Food & Drug Administration just approved Eli Lilly's GLP-1 pill orforglipron. 
Via The Motley Fool
News headline image
The Next Big AI Winner Might Not Be a Tech Company
Lilly’s AI push shows how non-tech firms can dominate the next wave. 
Via Barchart.com
Topics Artificial Intelligence
News headline image
The Second-Best Performing Vanguard ETF Over the Last Decade Is Issuing a 5-For-1 Stock Split. Here's Why It's a Screaming Buy in April. ↗
The Vanguard Mega Cap Growth ETF is down big from its highs as the largest tech stocks lead the broader market sell-off. 
Via The Motley Fool
Topics ETFs
News headline image
Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%
As of April 3, 2026, the financial landscape is witnessing a historic disconnect between gritty macroeconomic headlines and exuberant corporate fundamentals. Despite a backdrop of stubborn... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗
The drugmaker hasn't said its last word yet, as the weight-loss drug battle continues to heat up. 
Via The Motley Fool
News headline image
Where Will Viking Therapeutics Stock Be in 10 Years? ↗
There is a wide range of possibilities. 
Via The Motley Fool
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy ↗
Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuticals; Meanwhile, IO Biotech goes bankrupt. 
Via Benzinga
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff... 
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific... 
Via Finterra
Topics Economy Intellectual Property World Trade
News headline image
2 No-Brainer Vanguard ETFs to Buy During the Stock Market Sell-Off ↗
Throughout history, investors who bought during stock market declines while maintaining a long-term outlook yielded strong returns. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Dow, S&P 500, Nasdaq: From Morning Meltdown to Midday "Meh" ↗
Markets opened lower on Iran fears and a Tesla stumble, but bounced back. Here's what investors need to know about Thursday's volatile session. 
Via The Motley Fool
Topics Government Stocks World Trade
News headline image
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require... 
Via MarketMinute
Topics Economy
News headline image
Stock Market Rebounds Even As Oil Prices Skyrocket On Trump's Iran War Comments; Tesla, SpaceX, Eli Lilly In Focus: Weekly Review ↗
Tesla deliveries disappointed while Elon Musk's SpaceX filed for an IPO. 
Via Investor's Business Daily
Topics Government
News headline image
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience ↗
In a powerful demonstration of financial strength and strategic foresight, Eli Lilly and Company (NYSE: LLY) recently committed over $10 billion to two major initiatives in just a matter of days. While... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
How Novo Nordisk Is Striking Back As Eli Lilly Plans Its Newest Weight-Loss Launch ↗
Novo Nordisk said Thursday a new study suggests patients prefer its oral Wegovy over Eli Lilly's new GLP-1 pill, Foundayo. 
Via Investor's Business Daily
News headline image
The Evolution of The Cigna Group: A Deep Dive into a Health Services Powerhouse (2026)
April 2, 2026 Introduction The Cigna Group (NYSE: CI) stands today at a pivotal crossroads, having undergone one of the most significant strategic transformations in the modern healthcare era. Long... 
Via Finterra
Topics Artificial Intelligence Economy Lawsuit
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh ↗
Eli Lilly & Co shares are down Thursday despite FDA approval of its oral weight-loss drug Foundayo, as geopolitical tensions weigh on markets. 
Via Benzinga
News headline image
3 Monster Dividend Stocks to Hold for the Next 10 Years ↗
These are great and steady income providers for your portfolio. 
Via The Motley Fool
News headline image
Prediction: This Will Be Eli Lilly's Next Billion-Dollar Growth Driver. (Hint: It's Not Weight Loss Drugs.) ↗
Moves Lilly has recently made should support a new potential source of growth. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today ↗
GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026. 
Via Benzinga
News headline image
Why Eli Lilly Stock Trounced the Market Today ↗
Its first weight-loss pill was just approved by the FDA. 
Via The Motley Fool
News headline image
Stock Market Today, April 1: Markets Rally and Oil Prices Fall for Second Day Running ↗
Today, April 1, 2026, hopes that the Iran war may soon end drove markets upwards as tumbling oil prices reshaped the day’s winners. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Eli Lilly’s $47.8 Billion Masterstroke: The Contessa Acquisition and the New Era of Pharmaceutical Dominance
INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?
Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months. 
Via Barchart.com
News headline image
Could This New Approval Be a Turning Point For Novo Nordisk? ↗
The pharmaceutical giant still has plenty of work to do to recover from recent woes. 
Via The Motley Fool
News headline image
Why Is Eli Lilly Stock Gaining Today? ↗
Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market. 
Via Benzinga
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.7% in the afternoon session after the FDA approved Foundayo (orforglipro... 
Via StockStory
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.